PDF(Pubmed)
Abstract：
UNASSIGNED: Thyroglobulin autoantibodies (TgAbs) affect thyroglobulin immunometric assays (TgIMAs), causing falsely low results. Conversely, heterophilic antibodies (HAs) may cause falsely elevated results. Thyroglobulin (Tg) measurements by mass spectrometry (MS) resist antibody interference. The most effective use of TgIMA/TgMS in the evaluation of Tg remains unclear.
UNASSIGNED: The objective of this work was to study the usefulness of TgMS vs TgIMA in the presence of Tg measurement interference by HA and TgAb.
UNASSIGNED: In 163 thyroid cancer patients, Tg was postoperatively measured by TgIMA and TgMS. When TgIMA was elevated and TgMS undetectable, HA was assessed by serial dilution and pretreatment with HA blocking reagent. TgIMA and TgMS were compared in TgAb-positive patients with well-characterized clinical status.
UNASSIGNED: 6 out of 45 cases with TgIMA >1 ng/mL had undetectable TgMS. HA interference was confirmed by serial dilution and HA blocking reagent addition. In TgAb-positive cases, TgIMA and TgMS were highly correlated (R2 = 0.86). In patients with structural disease and TgAb, TgIMA and TgMS were detectable in 6/19 patients, and 9/19 cases, respectively. The TgMS concentration range in the 3 discrepant cases ranged from 0.5 to 2.0 ng/mL. Hence, the presence of TgAb was associated with inappropriately reduced Tg concentrations with both TgIMA and TgMS.
UNASSIGNED: HA cause falsely elevated TgIMA with undetectable TgMS with significant frequency. TgMS can be used to rule out HA interference. Albeit resistant to TgAb in vitro, TgMS detects little Tg in patients with TgAb and structural disease. Hence, TgAb may reduce Tg concentrations in vivo. The implication is that no assay design may be able to overcome this problem. TgMS may not detect structural disease in TgAb-positive patients.
UNASSIGNED: The objective of this work was to study the usefulness of TgMS vs TgIMA in the presence of Tg measurement interference by HA and TgAb.
UNASSIGNED: In 163 thyroid cancer patients, Tg was postoperatively measured by TgIMA and TgMS. When TgIMA was elevated and TgMS undetectable, HA was assessed by serial dilution and pretreatment with HA blocking reagent. TgIMA and TgMS were compared in TgAb-positive patients with well-characterized clinical status.
UNASSIGNED: 6 out of 45 cases with TgIMA >1 ng/mL had undetectable TgMS. HA interference was confirmed by serial dilution and HA blocking reagent addition. In TgAb-positive cases, TgIMA and TgMS were highly correlated (R2 = 0.86). In patients with structural disease and TgAb, TgIMA and TgMS were detectable in 6/19 patients, and 9/19 cases, respectively. The TgMS concentration range in the 3 discrepant cases ranged from 0.5 to 2.0 ng/mL. Hence, the presence of TgAb was associated with inappropriately reduced Tg concentrations with both TgIMA and TgMS.
UNASSIGNED: HA cause falsely elevated TgIMA with undetectable TgMS with significant frequency. TgMS can be used to rule out HA interference. Albeit resistant to TgAb in vitro, TgMS detects little Tg in patients with TgAb and structural disease. Hence, TgAb may reduce Tg concentrations in vivo. The implication is that no assay design may be able to overcome this problem. TgMS may not detect structural disease in TgAb-positive patients.
摘要：
未经证实：甲状腺球蛋白自身抗体（TgAbs）影响甲状腺球蛋白免疫测定（TgIMAs），导致错误的低结果。相反，异源性抗体（HAs）可能会导致结果错误升高。通过质谱(MS)的甲状腺球蛋白(Tg)测量抗抗体干扰。TgIMA/TgMS在Tg评估中的最有效用途仍不清楚。
UNASSIGNED：这项工作的目的是研究在HA和TgAb的Tg测量干扰存在下TgMSvsTgIMA的有用性。
未经证实：在163名甲状腺癌患者中，术后通过TgIMA和TgMS测量Tg。当TgIMA升高而TgMS检测不到时，通过连续稀释和用HA阻断试剂预处理来评估HA。在具有充分表征的临床状态的TgAb阳性患者中比较TgIMA和TgMS。
UNASSIGNED：45例TgIMA>1ng/mL的病例中有6例检测不到TgMS。通过连续稀释和添加HA阻断试剂确认HA干扰。在TgAb阳性病例中,TgIMA和TgMS高度相关(R2=0.86)。在患有结构性疾病和TgAb的患者中，在6/19患者中检测到TgIMA和TgMS，9/19例，分别。3种不同情况下的TgMS浓度范围为0.5至2.0ng/mL。因此，TgAb的存在与TgIMA和TgMS的Tg浓度不适当降低相关.
UASSIGNED：HA会导致TgIMA错误升高，TgMS无法检测到，频率明显。TgMS可用于排除HA干扰。尽管体外对TgAb具有抗性，TgMS在患有TgAb和结构性疾病的患者中检测不到Tg。因此，TgAb可以降低体内Tg浓度。这意味着没有试验设计能够克服这个问题。TgMS可能无法检测到TgAb阳性患者的结构性疾病。
UNASSIGNED：这项工作的目的是研究在HA和TgAb的Tg测量干扰存在下TgMSvsTgIMA的有用性。
未经证实：在163名甲状腺癌患者中，术后通过TgIMA和TgMS测量Tg。当TgIMA升高而TgMS检测不到时，通过连续稀释和用HA阻断试剂预处理来评估HA。在具有充分表征的临床状态的TgAb阳性患者中比较TgIMA和TgMS。
UNASSIGNED：45例TgIMA>1ng/mL的病例中有6例检测不到TgMS。通过连续稀释和添加HA阻断试剂确认HA干扰。在TgAb阳性病例中,TgIMA和TgMS高度相关(R2=0.86)。在患有结构性疾病和TgAb的患者中，在6/19患者中检测到TgIMA和TgMS，9/19例，分别。3种不同情况下的TgMS浓度范围为0.5至2.0ng/mL。因此，TgAb的存在与TgIMA和TgMS的Tg浓度不适当降低相关.
UASSIGNED：HA会导致TgIMA错误升高，TgMS无法检测到，频率明显。TgMS可用于排除HA干扰。尽管体外对TgAb具有抗性，TgMS在患有TgAb和结构性疾病的患者中检测不到Tg。因此，TgAb可以降低体内Tg浓度。这意味着没有试验设计能够克服这个问题。TgMS可能无法检测到TgAb阳性患者的结构性疾病。
